CN1827631A - Novel tyrosinase inhibitor and use thereof - Google Patents
Novel tyrosinase inhibitor and use thereof Download PDFInfo
- Publication number
- CN1827631A CN1827631A CN 200610034971 CN200610034971A CN1827631A CN 1827631 A CN1827631 A CN 1827631A CN 200610034971 CN200610034971 CN 200610034971 CN 200610034971 A CN200610034971 A CN 200610034971A CN 1827631 A CN1827631 A CN 1827631A
- Authority
- CN
- China
- Prior art keywords
- compound
- biphenyl
- tyrosinase inhibitor
- glucosyl group
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Cosmetics (AREA)
- Saccharide Compounds (AREA)
Abstract
The invention relates to a new tyrosinase inhibitor and its usage. The inventive content is that it provides biphenylglycosidicderivatives which can be used in the spheres of medicine and daily-use chemistry as melanin inhibiting agents or brightening agents, speaking in detail, it provides biphenylglycosidicderivatives represented by the above general formula (I), in which R1 stands for hydrogen, hydroxy,oxomethyl or gluconic group, R2 stands for hydrogen, hydroxyl or gluconic group, and R3 and R4 stand for hydrogen or gluconic group; and provides compositions with the said tyrosinase inhibitors. The new tyrosinase inhibitors and the compositions with the new compounds can be used as cosmetics to restrain melanin or brighten, medicines, externally used skin-care agent and so on.
Description
Technical field
The present invention relates to the biphenyl glucoside compound, be new tyrosinase inhibitor, be applied to medicine, food, filed of daily-use chemical industry as melanin inhibitor or whitening agent.
Background technology
The cutaneous pigmentation that reasons such as sun exposure cause, centering young adult, especially young women have become a big worry.Along with the raising of living standard, people increase day by day to the requirement of the skin that has health and whiten, and the consumption market is also in continuous expansion.
In recent years the pigmentation that studies have shown that is to generate enzyme by the melanochrome in the melanocyte in the UV-activated epidermis, and chromogenesis is caused.In the melanochrome generative process, tyrosine oxidase changes into DOPA with tyrosine, the DOPA quinone, through non-oxydasis and polymerization generate macromolecular melanochrome (Li Shaoyong etc. " Tianjin Normal University's journal " 2002,22:17-21).Therefore, the activity by restraint of tyrosinase can limit melanochrome and generate, and improves the pigmentation of skin.
At present existing multiple tyrosinase inhibitor is used for improving or the treatment skin splash, and commercialization, but still can not satisfy the needs of consumption market.Wherein, the stability of L-xitix is not good, the effect of kojic acid a little less than.Though quinhydrones has certain effect, it is oxidized to virose semiquinone base material under the tyrosine oxidase effect, makes melanocyte after birth lipid generation oxidation, causes membrane structure to destroy, and causes necrocytosis.Therefore, many countries forbid that quinhydrones uses in makeup.Arbutin as a kind of glycosides derivatives of quinhydrones, because of do not have cytotoxicity under active dose, is commodity and be developed to.But its whitening effect is unsatisfactory.Plants such as licorice, White Mulberry Root-bark, aloe north tradition is used for skin whitening.But these extracts reveal different effects because of place of production difference table often, are difficult to keep the steady quality of product.So effectively melanin inhibitor and whitening agent have wide consumption market.
Summary of the invention
The purpose of this invention is to provide a kind ofly has inhibiting new compound to tyrosine oxidase, is applied to prevent and treat the pigmentation of skins such as color spot, freckle, senile plaque and whiten.
Purpose of the present invention also comprises provides the composition that contains this new compound.
In order to address the above problem, present inventor's extraction separation from firethorn fruit obtains new tyrosinase inhibitor, is the biphenyl glycosides derivatives of being represented by following general formula I,
R wherein
1Be H, OH, OCH
3Or glucosyl group, R
2Be H, OH or glucosyl group, R
3, R
4Be H or glucosyl group.
Preferred R
1Be OCH
3, R
2, R
3Be H, R
4During for glucosyl group, chemistry 4 '-hydroxyl-2 by name, 3 ', 5 '-trimethoxy-(1,1 '-phenylbenzene)-2 '-oxygen-glucoside is called for short compound 1, and chemical structural formula is:
Preferred R
2, R
3, R
4Be H, R
1During for glucosyl group, chemistry 4 '-hydroxyl-3 ' by name, 5 '-dimethoxy-(1,1 '-phenylbenzene)-2-oxygen-glucoside is called for short compound 2, and chemical structural formula is:
Preferred R
1Be OH, R
3, R
4Be H, R
2During for glucosyl group, chemistry is called 2,4 '-dihydroxyl-3 ', and 5 '-dimethoxy-(1,1 '-phenylbenzene)-3-oxygen-glucoside is called for short compound 3, and chemical structural formula is:
Preferred R
1, R
4Be H, R
2Be OH, R
3During for glucosyl group, chemistry is called 3,4 '-dihydroxyl-3 ', and 5 '-dimethoxy-(1,1 '-phenylbenzene)-4-oxygen-glucoside is called for short compound 4, and chemical structural formula is:
New compound provided by the present invention, has significant restraint of tyrosinase effect, thereby the melanochrome in the inhibition melanocyte generates, to the skin tanning after the uviolizing and to the pigmentation of skins such as color spot, senile plaque, freckle with whiten and have good preventive and therapeutic effect.
Above-mentioned biphenyl glycosides derivatives I comprises that preferred any one compound 1～4 of institute all can be used as Melanin inhibitor or whitening agent, is applied to prevent and treat the pigmentation of skins such as color spot, freckle, senile plaque and whiten.And, available above-mentioned tyrosinase inhibitor is made composition, said composition contains any of above-mentioned biphenyl glycosides derivatives I or compound 1～4 or more than one tyrosinase inhibitor, and the pharmaceutical excipient that contains pharmaceutically to be allowed or conventional cosmetic base make medicine or makeup, as suppressing external composition for skin such as makeup that melanochrome generates or whiten, pharmaceuticals.As in composition, also adding the said biphenyl glycosides derivatives of the present invention I whitening agent composition in addition, cooperate by also using of whitening agent composition and biphenyl glycosides derivatives I, melanochrome be can further improve and inhibition effect and whitening effect generated.These whitening agent compositions can adopt but be not limited to following ingredients: L-xitix and derivative thereof and their salt, quinhydrones and derivative thereof and their salt, halfcystine and derivative thereof and their salt, kojic acid and derivative thereof and their salt, hydroxycinnamic acid and derivative thereof and their salt, gsh, plant milk extract such as Cortex Mori extract, Radix Glycyrrhizae extract, Aloe extract, Fructus Crataegi extract, the Flos rosae multiflorae extract, Bulbus Lilii extract, Radix Scutellariae extract, Rhizoma Chuanxiong extract, Radix Sophorae Flavescentis extract, Radix Angelicae Sinensis extract, Radix Bupleuri extract, Radix Et Rhizoma Rhei extract, Cortex Moutan extract, Pyracantha extract, liquirtin, isoliquiritin, intacellin etc.The whitening agent composition can be selected arbitrarily to mix more than a kind or 2 kinds.
Compound provided by the present invention and composition thereof can be made medicine or makeup, the visual different purposes of usage quantity and difference.
Preparation is during medicine, with this compound and conventional pharmaceutical carrier, as ointment base, emulsifying agent, tensio-active agent, stablizer, etc. make external preparations such as emulsion or ointment, preparation technology can adopt the drug preparation technique of routine.The consumption of its compound is proper with 0.5～3%.
Preparation can be added 0.1～1% compound of the present invention during makeup and get final product in cosmetic base.
Specifically, the present invention separates the compound that obtains from the fruit of Rosaceae Pyracantha plant fire sour jujube (Pyracantha fortuneana).Adopt the dry fruit of fiery sour jujube to be ground into meal, it is immersed cold carrying or reflux in extracting solvent in the extraction solvent, filter then or remove insolubles by method such as centrifugal, again gained is extracted solution and carry out concentrating under reduced pressure, adopt the exquisite means of known separation to separate afterwards and obtain above-mentioned biphenyl glycosides derivatives.
The solvent that is used to extract can adopt the solvent that is generally used for plant extract, for example, can be used alone or in combination organic solvent and water such as lower alcohols such as methyl alcohol, ethanol, acetoneand ethyl acetate.Extracting method can adopt ordinary method, and generally extracting temperature is 20-100 ℃, is preferably 40-80 ℃, and total extraction time is 1-48 hour, is preferably 4-16 hour.Extracting solution is by removing by filter insolubles, concentrating under reduced pressure.Extract is scattered in isopyknic water, uses chloroform extraction with system's solvent extration as elder generation successively, use n-butanol extraction again.Get the n-butanol extraction part, the vacuum decompression drying gets the butanols extract.Subsequently, obtain Compound I, and obtain compound 1～4 respectively with positive, anti-phase, gel chromatography separation and purification.
The invention has the beneficial effects as follows the composition that a kind of new tyrosinase inhibitor is provided and has contained this new compound, as suppressing external composition for skin such as makeup that melanochrome generates or whiten, pharmaceuticals.The present invention has obtained new tyrosinase inhibitor to have the skin tanning after the uviolizing, and to having good prevention, improvement and result of treatment because of cutaneous pigmentations such as the color spot that produces such as tanned, senile plaque, freckles.In addition, composition of the present invention by biphenyl glycosides derivatives and other whitening agent composition and with cooperating, can further improve melanochrome generation inhibition effect and whitening effect.
Below, by embodiment technical scheme of the present invention is elaborated.
Embodiment
The preparation of embodiment 1, the biphenyl glycosides derivatives represented with following formula I
Get the dry fruit of the fiery sour jujube (Pyracantha fortuneana) in the Qinling Mountains, Shaanxi, with 5 times of amount 60% ethanolic solns, thermal backflow is extracted three times, each 2 hours, united extraction liquid removed by filter insolubles, the filtrate decompression concentrate drying, dry thing is scattered in isopyknic water, uses chloroform successively, n-butanol extraction.The n-butanol extraction part, the vacuum decompression drying gets n-butyl alcohol extract.Subsequently, carry out chromatography, be respectively 10,30 with concentration, 50,70,95% aqueous ethanolic solution gradient elution with the open post of macroporous adsorbent resin; Get 30% aqueous ethanolic solution wash-out and partly carry out the open column chromatography of silica gel, with chloroform: methyl alcohol was respectively 20: 1, and 10: 1,4: 1,2: 1,1: 1 solution gradient wash-out, at chloroform: methyl alcohol is that 10: 1 wash-outs partly obtain total biphenyl glycosides derivatives.Get total biphenyl glycosides derivatives afterwards and carry out the open column chromatography of Toyopearl HW-40 gel, be respectively 20,40 with concentration, 60,100% methanol aqueous solution gradient elution; Get 40% methanol aqueous solution wash-out part and be prepared liquid phase separation,, successively obtain compound 1,2 with 15% acetonitrile solution wash-out through the octadecylsilane chemically bonded silica post; Get 60% methanol aqueous solution wash-out part and be prepared liquid phase separation,, successively obtain compound 3,4 with 15% acetonitrile solution wash-out through the octadecylsilane chemically bonded silica post.Identified their structure by physicochemical constant and modern Wave Spectrum means (IR, MS, NMR).
Compound 1 is faint yellow gluey thing.Structural formula is:
[α]
D 25-5.8 ° (c 1.45, MeOH), and UV collection of illustrative plates (MeOH) λ
Max(log ε) nm:206 (4.58) has phenyl ring to exist in 255 (3.62), 282 (3.69) prompting structures.IR collection of illustrative plates (KBr) v
MaxCm
-13430 are shown with hydroxyl exists, and 1630 is the characteristic absorbance of phenyl ring.ESI-MS provides quasi-molecular ion peak m/z 461[M+Na]
+, 437[M-H]
-, the prompting molecular weight is 438.HR-ESI-TOF-MS:m/z461.1425[M+Na]
+, theoretical value is 461.1424 (C
21H
26O
10Na), thus determine that molecular formula is C
21H
26O
10, degree of unsaturation is 9.
1Among the H-NMR, can observe 5 fragrant proton signals and three methoxyl group signals (δ 3.77,3.70,3.69).According to coupling constant, contain one 1 in the prompting structure, the 2-disubstituted benzenes [δ 7.38 (1H, d, J=7.6Hz), 7.24 (1H, t, J=7.6Hz), 6.99 (1H, d, J=7.6Hz), and6.89 (1H, t, J=7.6Hz)] and one 1,2,3,4, (δ 6.44,1H) for 5-five substituted benzenes.In addition, in conjunction with hsqc spectrum, all the other hydrogen signals have shown the existence of glucosyl group in the structure.In the HMBC spectrum, connect oxygen carbon signal δ 156.6 and H-4 (δ 7.24), H-6 (δ 7.38) is relevant, is belonged to be C-2; Two oxygen carbon signal δ 140.8,140.8 of company are relevant with H-6 ' (δ 6.44) in addition, belonged to be C-2 ', C-4 '.Relevant with C-2 respectively by two methoxyl group signal δ 3.69,3.70 with C-3 ' (δ 140.9), pointed out them to be connected to C-2 and C-3 '.HMBC relevant peaks H-6 ' (δ 6.44)/C-1 (δ 127.4) shows that its aglycon structure is 1, the 1 ' biphenyl that links to each other.Sugar terminal hydrogen H-1 " (δ 4.69,1H, and d, J=7.6Hz) relevant with C-4, prompting glucose is connected 4 of aglycon.In the ROESY spectrum, methoxyl group signal δ 3.77 is relevant with H-6 ', shows that it is connected on 5 ' of aglycon.Thereby the structure of compound 1 is confirmed as 4 '-hydroxyl-2,3 ', 5 '-trimethoxy-(1,1 '-phenylbenzene)-2 '-oxygen-glucoside.
Compound 2 is faint yellow gluey things.Structural formula is
[α]
D 17-36.1 ° (c 0.39, MeOH), and UV collection of illustrative plates (MeOH) λ
Max(log ε) nm:205 (4.17) has phenyl ring to exist in 269 (3.47), 286 (sh) (3.45) prompting structure.IR collection of illustrative plates (KBr) v
MaxCm
-13438 are shown with hydroxyl exists, and 1644 is the characteristic absorbance of phenyl ring.ESI-MS provides quasi-molecular ion peak m/z 431[M+Na]
+, 407[M-H]
-, the prompting molecular weight is 408.HR-ESI-TOF-MS:m/z 431.1343[M+Na]
+, theoretical value is 431.1318 (C
20H
24O
9Na), thus determine that molecular formula is C
20H
24O
9, degree of unsaturation is 9.
1Among the H-NMR, can observe 6 fragrant protons and two methoxyl groups (δ 3.79,6H, s).According to coupling constant, contain one 1 in the prompting structure, the 2-disubstituted benzenes [δ 7.35 (1H, d, J=8.0Hz), 7.25 (1H, t, J=8.0Hz), 7.19 (1H, d, J=8.0Hz), and 7.04 (1H, t, and one 1,3,4 J=8.0Hz)], and 5-four substituted benzenes (δ 6.91,2H, brs).In addition, in conjunction with HSQC, the residual hydrogen signal indicating existence of glucosyl group in the structure.In the ROESY spectrum, and the methoxyl group proton (δ 3.79,6H, and s) with the fragrant proton H-2 ' of two chemical equivalence, 6 ' (δ 6.91, and 2H is brs) relevant, points out them to be connected C-3 ', 5 ' (δ 147.5).Fragrance proton δ 6.99,7.24,6.89,7.38 is relevant in turn in the COSY spectrum, splits the feature of branch in conjunction with being coupled, and is belonged to be H-2, H-3, H-4, H-5.HMBC relevant peaks H-2 ', 6 '/C-1 (δ 130.2) shows that its aglycon structure is 1, the 1 ' biphenyl that links to each other.Sugar terminal hydrogen H-1 " and (δ 5.07,1H, and d, J=7.8Hz) relevant with H-3 in the ROESY spectrum, prompting glucose is connected 2 of aglycon.Thereby the structure of compound 2 is confirmed as 4 '-hydroxyl-3 ', 5 '-dimethoxy-(1,1 '-phenylbenzene)-2-oxygen-glucoside.
Compound 3 is faint yellow gluey things.Structural formula is
[α]
D 17-46.4 ° (c 0.79, MeOH), and UV collection of illustrative plates (MeOH) λ
Max(log ε) nm:210 (4.36) has phenyl ring to exist in 267 (3.78), 291 (sh) (3.67) prompting structure.IR collection of illustrative plates (KBr) v
MaxCm
-13427 are shown with hydroxyl exists, and 1625 is the characteristic absorbance of phenyl ring.ESI-MS provides quasi-molecular ion peak m/z 447[M+Na]
+, 423[M-H]
-, the prompting molecular weight is 424.HR-ESI-TOF-MS:m/z 447.1275[M+Na]
+, theoretical value is 447.1267 (C
20H
24O
10Na), thus determine that molecular formula is C
20H
24O
10, degree of unsaturation is 9.
The hydrogen spectrum of compound 3 is very similar to compound 2, has just lacked a fragrant proton signal than 2 hydrogen spectrum, and there is one 1 in prompting in 3 structure, 2,3-trisubstituted benzene [δ 7.07 (1H, d, J=7.6Hz), 6.98 (1H, d, J=7.6Hz) and 6.74 (1H, t, J=7.6Hz)], but not 1, the 2-disubstituted benzenes.Fragrance proton δ 7.07,6.74,6.98 is relevant in turn in COSY, splits the branch feature in conjunction with coupling, is belonged to be H-4, H-5, H-6.Sugar terminal hydrogen H-1 " (δ 4.60,1H, and d, J=6.8Hz) relevant with C-3 (δ 146.0) in the HMBC spectrum, prompting glucose is connected 3 of aglycon.Thereby the structure of compound 3 is confirmed as 2,4 '-dihydroxyl-3 ', 5 '-dimethoxy-(1,1 '-phenylbenzene)-3-oxygen-glucoside.
Compound 4 is faint yellow gluey things.Structural formula is
[α]
D 17-41.6 ° (c 0.25, MeOH), and UV collection of illustrative plates (MeOH) λ
Max(log ε) nm:210 (4.66) has phenyl ring to exist in 263 (4.07), 296 (sh) (3.92) prompting structure.IR collection of illustrative plates (KBr) v
MaxCm
-13431 are shown with hydroxyl exists, and 1630 is the characteristic absorbance of phenyl ring.ESI-MS provides quasi-molecular ion peak m/z 447[M+Na]
+, 423[M-H]
-, the prompting molecular weight is 424.HR-ESI-TOF-MS:m/z 447.1249[M+Na]
+, theoretical value is 447.1267 (C
20H
24O
10Na), thus determine that molecular formula is C
20H
24O
10, degree of unsaturation is 9.
1Among the H-NMR, can observe 5 fragrant protons and two methoxyl groups (δ 3.79,6H, s).According to coupling constant, contain one 1,4 in the prompting structure, the 5-trisubstituted benzene [δ 7.02 (1H, brd, J=8.8Hz), 6.72 (1H, d, J=3.0Hz), 6.62 (1H, dd, J=8.8,3.0Hz)] and one 1,3,4,5-four substituted benzenes (δ 6.87,2H, brs).In addition, in conjunction with HSQC, the residual hydrogen signal indicating existence of glucosyl group in the structure.In the ROESY spectrum, and the methoxyl group proton (δ 3.77,6H, and s) with the fragrant proton H-2 ' of two chemical equivalence, 6 ' (δ 6.87, and 2H is brs) relevant, points out them to be connected C-3 ', 5 ' (δ 147.4).In the HMBC spectrum, two even oxygen carbon signal δ 151.9,146.8 respectively with H-2 (δ 6.72), H-5 (δ 7.02) and H-2, H-5, H-6 (δ 6.62) is relevant, therefore is C-3, C-4 by ownership.HMBC relevant peaks H-2/C-1 ' (δ 128.0) shows that its aglycon structure is 1, the 1 ' biphenyl that links to each other.Sugar terminal hydrogen H-1 " and (δ 4.89,1H, and d, J=7.7Hz) relevant with C-4 in the HMBC spectrum, prompting glucose is connected 4 of aglycon.Thereby the structure of compound 4 is confirmed as 3,4 '-dihydroxyl-3 ', 5 '-dimethoxy-(1,1 '-phenylbenzene)-4-oxygen-glucoside.
Table 1: compound 1-5's
13C-NMR data (100MHz for
13C)
a
| Sequence number | 1 | 2 | 3 | 4 |
| 1 | 127.4 | 130.2 | 128.4 | 131.4 |
| 2 | 156.6 | 153.9 | 143.8 | 116.5 |
| 3 | 111.1 | 114.5 | 146.0 | 151.9 |
| 4 | 128.0 | 127.6 | 115.4 | 146.8 |
| 5 | 119.6 | 121.8 | 118.4 | 116.5 |
| 6 | 132.3 | 130.4 | 124.0 | 114.0 |
| 1’ | 121.3 | 127.5 | 128.4 | 128.0 |
| 2’ | 140.8 | 107.2 | 106.9 | 107.1 |
| 3’ | 140.9 | 147.5 | 147.4 | 147.4 |
| 4’ | 140.8 | 134.7 | 134.7 | 134.7 |
| 5’ | 143.9 | 147.5 | 147.4 | 147.4 |
| 6’ | 109.6 | 107.2 | 106.9 | 107.1 |
| 1” | 102.2 | 100.0 | 103.4 | 101.1 |
| 2” | 73.8 | 73.5 | 73.3 | 73.6 |
| 3” | 76.3 | 77.0 | 75.7 | 76.9 |
| 4” | 69.7 | 69.7 | 69.9 | 69.8 |
| 5” | 76.8 | 77.1 | 77.3 | 77.0 |
| 6” | 60.8 | 60.6 | 60.8 | 60.8 |
| 2-OCH 3 | 55.3 | |||
| 3’-OCH 3 | 60.2 | 56.0 | 56.0 | 56.0 |
| 5’-OCH 3 | 56.0 | 56.0 | 56.0 | 56.0 |
Annotate::
aAt DMSO-d
6Middle test.
Embodiment 2: the mensuration of tyrosinase inhibitory activity
Test sample: get the compound 1-4 that embodiment 1 makes, tyrosine oxidase extracts from mushroom available from Sigma company.
Reference substance: arbutin
Test method: at first substrate L-tyrosine is dissolved in the phosphate buffer solution (25mM, pH 6.8) and reaches 0.1mg/mL concentration.In 96 orifice plates, add the above-mentioned substrate solution of 40 μ L, 80 μ L phosphoric acid buffers (25mM, pH 6.8), and 40 μ L are with 20% methanol-water dissolved formula (I).20% methanol-water adding blank with 40 μ L is aerial.The phosphate buffer solution (pH 6.8 for 100U/mL, 25mM) that adds 40 μ L tyrosine oxidases begins reaction, incubates 30 minutes 37 ℃ of following temperature.Before and after incubating, temperature under 492nm, measures the absorbancy in every hole.
According to the inhibiting rate (%) of the absorbancy computerized compound (I) under 492nm, and be IC with the concentration determination that enzymic activity inhibiting rate (%) reaches 50% o'clock inhibitor to tyrosine oxidase
50Value.Inhibiting rate (%) can calculate according to following formula,
Inhibiting rate (%)=[(A-B)-(C-D)]/(A-B) * 100
In the following formula, A represents that temperature incubates the back absorbancy of blank well under 492nm,
B represent temperature incubate before the absorbancy of blank well under 492nm,
C represents that temperature incubates the back absorbancy of sample well under 492nm,
D represent temperature incubate before the absorbancy of sample well under 492nm.
Result: see Table 2
Table 2 tyrosinase inhibitory activity
| Compound number | IC 50(mM) |
| 1 | 2.21 |
| 2 | 0.45 |
| 3 | 0.07 |
| 4 | 0.14 |
| Arbutin | 0.23 |
Conclusion: go up table 2 as can be seen, all samples shows tyrosinase inhibitory activity in experiment in vitro, and especially the inhibition activity of compound 3,4 is better than the reference substance arbutin.
Embodiment 3: whitening cream
Prescription: compound 3 0.1g halfcystine 0.1g
Stearic acid 10.0g hexadecanol 4.5g
Wool grease 1.0g propylene glycol 15.0g
Trolamine 0.7g sodium lauryl sulphate 0.5g
Ethyl p-hydroxybenzoate 0.1g distilled water 68.ml
Method for making: get stearic acid, hexadecanol, wool grease mixing; Other gets compound, propylene glycol, trolamine, sodium lauryl sulphate, ethyl p-hydroxybenzoate, distilled water mixing, places beaker to be heated to fusing or dissolving respectively, is kept to stir down about 70 ℃ oil phase is added to aqueous phase, stirs to condensation, promptly
Embodiment 4, cleawhite pack
Prescription: (1) PVA 14g sorbyl alcohol 2g
Sodium laurylsulfate 3g glycerine 2.5g
Tween-80 2.5g compound 2 0.05g
Compound 3 0.05g add to distilled water 100g
(2) PVA 14g glycerine 2.5g
Tween-80 2.5g distilled water adds to 100g
(3) ethyl cellulose 5g chloroform adds to 100ml
Method for making: earlier (1) slurry is filmed, dry back is coated with (2) slurry on face, be coated with (3) solution after the drying, dry rear demoulding, shearing, packing.
Embodiment 5: sunlight lotion
Prescription: glycerine 5g hyaluronate sodium 0.5g
Potassium hydroxide 0.1g ethanol 10g
Vitamin-E 0.5g tween 80 2g
Compound 3 0.1g essence are an amount of
Water adds to 100ml
Embodiment 6: essence
Prescription: glycerine 5g hyaluronate sodium 0.3g
Polyoxyethylene 2g ethanol 10ml
An amount of ethyl p-hydroxybenzoate 0.1g of essence
Compound 4 0.1g water add to 100ml
Embodiment 7: drive spot ointment
Prescription: compound 3 0.5g compounds 4 0.5g
Resorcinol 1.0g wool grease 10g
Vaseline 76.6g mentha camphor 5g
Method for making: get compound 3,4, Resorcinol, mentha camphor and put mixing in the mortar, the wool grease, the Vaseline that add an amount of fusing grind, and gradation adds remaining wool grease, Vaseline and grinds well promptly again.
Embodiment 8 ointment
Prescription: stearic acid 12g single stearic acid glycerine lipoprotein 3.5g
White oil 6g Vaseline 5g
Wool grease 5g trolamine 0.5g
Ethyl p-hydroxybenzoate 0.1g compound 4 1g
Water 73ml
Method for making: get stearic acid, single stearic acid glycerine lipoprotein, white oil, Vaseline and wool grease and put and make fusing about beaker internal heating to 80 fully; Trolamine, ethyl p-hydroxybenzoate, compound 4 and water are heated to about 80 ℃, stir to be added to down in the mixed solution of getting stearic acid etc., to emulsification are.
Embodiment 9: the sample of comparing embodiment 3 and embodiment 8 is to the mensuration of beauty of human body white effect
Test method: with 30 healthy volunteers that obvious senile plaque and freckle are arranged, be divided into three groups, 10 every group, test group is smeared the sample of embodiment 3 or 8 in every morning with before falling asleep, and control group is not embrocated any makeup.The state of cosmetic on the throne is taken the photochrome after experiment beginning day and 4 weeks down, and range estimation compares to determine and test the colour of skin state of comparing beginning day.
Result: see Table of the comparison of the sample of 3 embodiment 3 and embodiment 8 to beauty of human body white effect
| Color is obviously desalinated | Color is slightly desalinated | No change or color increase the weight of | |
| Embodiment 8 | 6 examples | 3 examples | 1 example |
| Embodiment 3 | 3 examples | 5 examples | 2 examples |
| Control group | 0 example | 0 example | 10 examples |
Conclusion: as can be seen from Table 3, the embodiment 3,8 that contains the biphenyl glycosides derivatives all has whitening effect preferably.
Claims (7)
1, a kind of tyrosinase inhibitor, by the biphenyl glycosides derivatives of following general formula (I) expression,
R wherein
1Be H, OH, OCH
3Or glucosyl group, R
2Be H, OH or glucosyl group, R
3, R
4Be H or glucosyl group.
2, by the tyrosinase inhibitor of claim 1, it is characterized in that the R in the biphenyl glycosides derivatives
1Be OCH
3, R
2, R
3Be H, R
4Be glucosyl group, chemistry 4 '-hydroxyl-2 by name, the compound (1) of 3 ', 5 '-trimethoxy-(1,1 '-phenylbenzene)-2 '-oxygen-glucoside.
3, by the tyrosinase inhibitor of claim 1, it is characterized in that the R in the biphenyl glycosides derivatives
2, R
3, R
4Be H, R
1Be glucosyl group, chemistry 4 '-hydroxyl-3 ' by name, the compound (2) of 5 '-dimethoxy-(1,1 '-phenylbenzene)-2-oxygen-glucoside.
4, by the tyrosinase inhibitor of claim 1, it is characterized in that the R in the biphenyl glycosides derivatives
1, R
3, R
4Be H, R
2Be glucosyl group, chemistry is called 2,4 '-dihydroxyl-3 ', the compound (3) of 5 '-dimethoxy-(1,1 '-phenylbenzene)-3-oxygen-glucoside.
5, by the tyrosinase inhibitor of claim 1, it is characterized in that the preferred R in the biphenyl glycosides derivatives
1, R
4Be H, R
2, OH, R
3Be glucosyl group, chemistry is called 3,4 '-dihydroxyl-3 ', the compound (4) of 5 '-dimethoxy-(1,1 '-phenylbenzene)-4-oxygen-glucoside.
6, a kind of composition wherein contains just like represented any of claim 1 formula of I or more than one tyrosinase inhibitor, and the pharmaceutical excipient that contains pharmaceutically to be allowed or conventional cosmetic base medicine or the makeup made.
7, a kind of purposes as represented any of claim 1 formula of I or more than one tyrosinase inhibitor is as Melanin inhibitor or whitening agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100349713A CN100355768C (en) | 2006-04-13 | 2006-04-13 | Novel tyrosinase inhibitor and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100349713A CN100355768C (en) | 2006-04-13 | 2006-04-13 | Novel tyrosinase inhibitor and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1827631A true CN1827631A (en) | 2006-09-06 |
| CN100355768C CN100355768C (en) | 2007-12-19 |
Family
ID=36946205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100349713A Expired - Fee Related CN100355768C (en) | 2006-04-13 | 2006-04-13 | Novel tyrosinase inhibitor and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100355768C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101139377B (en) * | 2007-10-19 | 2010-08-25 | 暨南大学 | Dibenzofuran glycoside derivative having tyrosinase inhibitory action and uses thereof |
| CN102077925A (en) * | 2010-12-09 | 2011-06-01 | 广东省微生物研究所 | Preparation for promoting synthesis and dendritic dispersion of skin melanin of fishes |
| CN106220504A (en) * | 2016-08-02 | 2016-12-14 | 重庆工商大学 | A kind of Flos Moutan is extracted method and the application of ethylparaben |
| CN107714557A (en) * | 2017-11-24 | 2018-02-23 | 重庆工商大学 | Method and the application of tyrosinase inhibitor are extracted in a kind of fruit from Pyracantha |
| CN113476356A (en) * | 2021-04-30 | 2021-10-08 | 云南英格生物技术有限公司 | Preparation method and application of pyracantha fortuneana fruit extract |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10324566A1 (en) * | 2003-05-30 | 2004-12-16 | Symrise Gmbh & Co. Kg | Use of diphenylmethane derivatives as tyrosinase inhibitors |
-
2006
- 2006-04-13 CN CNB2006100349713A patent/CN100355768C/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101139377B (en) * | 2007-10-19 | 2010-08-25 | 暨南大学 | Dibenzofuran glycoside derivative having tyrosinase inhibitory action and uses thereof |
| CN102077925A (en) * | 2010-12-09 | 2011-06-01 | 广东省微生物研究所 | Preparation for promoting synthesis and dendritic dispersion of skin melanin of fishes |
| CN102077925B (en) * | 2010-12-09 | 2012-09-05 | 广东省微生物研究所 | Preparation for promoting synthesis and dendritic dispersion of skin melanin of fishes |
| CN106220504A (en) * | 2016-08-02 | 2016-12-14 | 重庆工商大学 | A kind of Flos Moutan is extracted method and the application of ethylparaben |
| CN106220504B (en) * | 2016-08-02 | 2018-08-17 | 重庆工商大学 | The method of extraction ethyl-para-hydroxybenzoate and application in a kind of peony |
| CN107714557A (en) * | 2017-11-24 | 2018-02-23 | 重庆工商大学 | Method and the application of tyrosinase inhibitor are extracted in a kind of fruit from Pyracantha |
| CN107714557B (en) * | 2017-11-24 | 2021-07-09 | 重庆工商大学 | Method for extracting tyrosinase inhibitor from pyracantha fruit and application of tyrosinase inhibitor |
| CN113476356A (en) * | 2021-04-30 | 2021-10-08 | 云南英格生物技术有限公司 | Preparation method and application of pyracantha fortuneana fruit extract |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100355768C (en) | 2007-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5377312B2 (en) | Method for producing icariside II, cosmetic composition containing the same and use thereof for skin whitening | |
| JP5430891B2 (en) | Melanin production inhibitor | |
| CN108567912B (en) | Traditional Chinese medicine extract and enzymolysis and fermentation product thereof | |
| CN1318366A (en) | Cosmetics composition | |
| CN1812795A (en) | Composition for external use | |
| CN114376952B (en) | Paeonia lactiflora extract and preparation method and application thereof | |
| CN101139377B (en) | Dibenzofuran glycoside derivative having tyrosinase inhibitory action and uses thereof | |
| CN1827631A (en) | Novel tyrosinase inhibitor and use thereof | |
| JP2010024208A (en) | Ucp2 expression promotor | |
| WO2022215441A1 (en) | Novel polyphenol compound | |
| KR20140100117A (en) | Compositions comprising the extract of Alnus japonica or the compounds derived therefrom for inhibiting adipogenesis | |
| CN111135159B (en) | Application of diterpene compound in preparation of tyrosinase inhibitor | |
| CN102796112A (en) | Prenylflavonoid compound and application thereof in preparation of pancrelipase inhibitor | |
| CN1561222A (en) | Matrix metalloprotease inhibitor | |
| CN100408023C (en) | Cosmetic composition having whitening effect comprising extract of pulsatilla radix as main ingredient | |
| JP2008214335A (en) | Sparassis crispa extract, biaryl compound and cosmetic | |
| JP2004352697A (en) | Tyrosinase expression inhibitor | |
| CN105326779A (en) | Moisturizing, brightening and whitening hair gel and preparation method thereof | |
| CN100560050C (en) | Herba Cistanches total glycosides reaches the application of brightening in the cosmetic purpose compositions in preparation by suppressing cutaneous pigmentation | |
| CN104761445A (en) | Method for extracting chemical components from root of mongolian medicine Cymbaria dahurica | |
| JP2003171307A (en) | Matrix metalloprotease inhibitor | |
| CN114836482A (en) | Preparation method of oxyresveratrol | |
| CN117529487A (en) | Novel phenylpropanoid compounds | |
| JP2007063191A (en) | New bleaching agent | |
| CN102250161B (en) | Ionoionone analog derivative with tyrosinase inhibitory activity and its production and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071219 Termination date: 20150413 |
|
| EXPY | Termination of patent right or utility model |